CI

At a glance

ClinicalIndex Comparison Record
Phase 1Enrolling by Invitation· 20 target
Drug / intervention
OC-EIEsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03393962
NCT03393962Phase 1Enrolling by InvitationOn Track
CompareCT.gov

Interventional Treatment of Ovarian Cancer With Cancer Antigen-specific Engineered Immune Effector T Lymphocytes (OC-EIEs)

Shenzhen Geno-Immune Medical Institute·interventional·Posted Jan 9, 2018·Updated Jun 23, 2026

In Brief

A Phase 1 clinical trial evaluating OC-EIEs for Ovarian Cancer. Currently enrolling by invitation, targeting 20 participants across 1 site.

Detailed Summary

This is a single-arm, open-label, phase I/II trial to evaluate the safety and efficacy of ovarian cancer-specific, engineered immune effectors (OC-EIEs) in women.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesChina
Collaborators--

Timeline

Phase 1Enrolling by Invitation
201820192020202120222023202420252026202720282029
First PostedJan 9, 2018
Enrollment StartDec 1, 2025
Primary CompletionJan 31, 2028
Study CompletionDec 31, 2028
TodayJul 1, 2026
Enrollment to primary: 2.2 yearsPosted 8.5 years agoPrimary completion in 1.6 years

Arms & Interventions

OC-EIEsexperimental

Autologous ovarian cancer antigen-specific cytotoxic lymphocytes

Biological: OC-EIEs

Interventions

OC-EIEsbiological

2 to 4 infusions, once a week, 0.1\~4x10\^6 CTLs/kg; injection via IV, abdominal cavity or intrastumoral.